Dr Megan Baldwin, CEO & Managing Director, Opthea Limited added “We continue to be encouraged by the positive outcomes of the further analyses of the Phase 2b trial. We anticipate reporting additional outcomes from the study over the following months at international ophthalmology meetings.”
The next presentation will be at the American Academy of Ophthalmology's annual meeting in San Francisco, October 12, 2019 to October 15, 2019.
Dr Megan Baldwin, CEO & Managing Director, Opthea Limited added...
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $695.5M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 248 | 57.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 3439 | 1 |
View Market Depth
| Last trade - 09.50am 04/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |
Day chart unavailable